Your Source for Venture Capital and Private Equity Financings

Colossal Biosciences Inks $150M Series B

DALLAS, TX, Colossal Biosciences, the world's first de-extinction company, has announced an oversubscribed $150 million Series B financing.
The round was led by United States Innovative Technology Fund, with participation from Breyer Capital, WestRiver Group, Bob Nelsen, Animal Capital, Victor Vescovo, In-Q-Tel, Animoca Brands, Peak 6, BOLD Capital, and Jazz Ventures, among others.

As part of its Series B, Colossal has also announced the launch of its Avian Genomics Group, which will pursue the de-extinction of the iconic Dodo, a bird species that was wiped out of its native ecosystem, Mauritius, as a direct result of human settlement and ecosystem competition in 1662.

Colossal was founded by emerging technology and software entrepreneur Ben Lamm and world-renowned geneticist and serial biotech entrepreneur George Church, Ph.D., and is the first to apply CRISPR technology for the purposes of species de-extinction. Colossal creates innovative technologies for species restoration, critically endangered species protection and the repopulation of critical ecosystems that support the continuation of life on Earth. Colossal is accepting humanity's duty to restore Earth to a healthier state, while also solving for the future economies and biological necessities of the human condition through cutting-edge science and technologies.
(c) by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000+ startups and 5,000+ VC investors